Papers by abdulla Alhasso
Clinical Oncology, Dec 31, 2023
Clinical Oncology, Oct 31, 2023
British Journal of Radiology, Dec 1, 2012
Objectives: Our aim was to clinically commission an online seed matching imageguided radiotherapy... more Objectives: Our aim was to clinically commission an online seed matching imageguided radiotherapy (IGRT) protocol using modern hardware/software for patients undergoing prostate radiotherapy. An essential constraint was to achieve this within a busy centre without reducing patient throughput, which had been reported with other techniques. Methods: 45 patients had 3 fiducial markers inserted into the prostate and were imaged daily using kilovoltage orthogonal images with online correction applied before treatment. A total of 1612 image pairs were acquired and analysed to identify interfractional motion, seed migration and interobserver variability, and assess ease of use. Results: This method of IGRT was implemented successfully in our centre with no impact on treatment times and patient throughput. Systematic (S) interfractional setup errors were 2.2, 2.7 and 3.9 mm in right-left (RL), superoinferior (SI) and anteroposterior (AP) directions, respectively. Random (s) interfractional setup errors were 3.2 (RL), 3.7 (SI) and 5.7 mm (AP). There were significant differences between patients. Seed migration and interobserver variability were not significant issues. Conclusions: The described technique is facilitated by the advanced imaging system, allowing a fast and effective method of correcting setup errors before treatment. Extended implementation of this technique has improved treatment delivery to the majority of our prostate radiotherapy patients. The measurement of interfractional motion in this study is potentially valuable for margin reduction in intensity-modulated radiotherapy/volumetric arc therapy. Advances in knowledge: This technique can be used within treatment time constraints, benefiting large numbers of patients by helping to avoid geographical miss and potentially reducing toxicity to organs at risk.
Annals of Oncology, May 1, 2019
Background: There is a growing body of evidence supporting the omission of adjuvant chemotherapy ... more Background: There is a growing body of evidence supporting the omission of adjuvant chemotherapy in a subset of estrogen receptor (ER) positive (þ) / Her2 receptor negative (-) breast cancer patients. We assessed recent trends in the administration of adjuvant chemotherapy thereby evaluating the role of the 70-gene signature (70-GS) testing in decision-making in the systemic treatment of lymph node negative (N0) and lymph node positive (Nþ) breast cancer patients. Methods: Patients with a national guideline directed indication for 70-GS use treated between 2013-2016 were selected from the Netherlands Cancer Registry (NCR). Time trends in the administration of adjuvant chemotherapy were evaluated within guideline-and age delineated subgroups. The influence of the 70-GS on chemotherapy use was assessed with logistic regression. Results: During the study period, the overall administration of adjuvant chemotherapy decreased from 49% to 23%. For N0 patients, the decline in chemotherapy was independent of 70-GS use, whereas in N1a disease, the 70-GS was associated with a consistent lower proportion of patients receiving chemotherapy throughout the study period (OR 0.21 95% CI: 0.15-0.29). In patients <50 years and 50-59 years of age, the 70-GS use was associated with less chemotherapy administration and remained independently associated with less chemotherapy use after adjustment by multivariable logistic regression (OR 0.17, 95% CI: 0.13-0.23 and OR 0.53 95% CI: 0.43-0.65). Conclusions: During a period that chemotherapy administration declined in ERþ breast cancer, the 70-GS contributed to the observed decrease in node positive disease and in younger patients. In N0 patients, the decline in chemotherapy use was independent of the 70-GS. A more selective use of gene-expression analyses is propagated.
Radiotherapy and Oncology, May 1, 2012
Radiotherapy and Oncology, May 1, 2017
Conference abstract. Part of special issue: ESTRO 36, May 5-9, 2017, Vienna, Austria
Radiotherapy and Oncology, Apr 1, 2018
5 university hospital and faculty of medicine c.g. carus-tu dresden-national center for tumor dis... more 5 university hospital and faculty of medicine c.g. carus-tu dresden-national center for tumor diseases dresden, dept. Of nuclear medicine, dresden, germany 6 helmholtz-zentrum dresden-rossendorf, institute of radiopharmaceutical cancer research, dresden, germany 7 university hospital and faculty of medicine c.g. carus-tu dresden-national center for tumor diseases dresden, dept. Of neurosurgery, dresden, germany 8 german cancer consortium german cancer research center dkfz heidelberg-university hospital and faculty of medicine c.g. carus-tu dresden-helmholtz-zentrum dresden-rossendorf, dept. Of radiooncology, dresden, germany 9 german cancer research center dkfz heidelberguniversity hospital and faculty of medicine c.g. carus-tu dresden, dept. Of radiology, dresden, germany
European Urology, Jun 1, 2016
Background: Luteinising hormone-releasing hormone agonists ([ 2 1 _ T D $ D I F F ] LHRHa), used ... more Background: Luteinising hormone-releasing hormone agonists ([ 2 1 _ T D $ D I F F ] LHRHa), used as androgen deprivation therapy (ADT) in prostate cancer (PCa) management, reduce serum oestradiol as well as testosterone, causing bone mineral density (BMD) loss. Transdermal oestradiol is a potential alternative to LHRHa. Objective: To compare BMD change in men receiving either LHRHa or oestradiol patches
Radiotherapy and Oncology
Radiotherapy and Oncology, 2021
Journal of Clinical Oncology, 2009
e11616 Aims: It is well known that aromatase inhibitors (AI) are associated with significant redu... more e11616 Aims: It is well known that aromatase inhibitors (AI) are associated with significant reduction in bone mineral density (BMD) through suppression of estrogen production. This effect has been confirmed in several studies. It is considered important that we evaluate our patients and assess their baseline BMD in the adjuvant setting in relation to the use of AIs. Methods: 122 patients on adjuvant AI were evaluated retrospectively. AIs were used either as upfront, early switch or extended adjuvant therapy. BMD (T score for hip and lumbar spine) was evaluated using DEXA scanning at baseline and annually thereafter. Risk factors for osteoporosis were assessed prior to each scan. Results: Mean baseline T scores for lumbar spine and hip were - 0.95 and - 0.79 respectively. The corresponding T scores after 1 year of treatment were -1.06 and -0.92 respectively. This represents 10.6% and 17.4% reduction in T scores for the spine and hip. 24 patients (19.7%) required anti osteoporosis th...
Radiotherapy and Oncology, 2018
5 university hospital and faculty of medicine c.g. carus-tu dresden-national center for tumor dis... more 5 university hospital and faculty of medicine c.g. carus-tu dresden-national center for tumor diseases dresden, dept. Of nuclear medicine, dresden, germany 6 helmholtz-zentrum dresden-rossendorf, institute of radiopharmaceutical cancer research, dresden, germany 7 university hospital and faculty of medicine c.g. carus-tu dresden-national center for tumor diseases dresden, dept. Of neurosurgery, dresden, germany 8 german cancer consortium german cancer research center dkfz heidelberg-university hospital and faculty of medicine c.g. carus-tu dresden-helmholtz-zentrum dresden-rossendorf, dept. Of radiooncology, dresden, germany 9 german cancer research center dkfz heidelberguniversity hospital and faculty of medicine c.g. carus-tu dresden, dept. Of radiology, dresden, germany
Journal of Clinical Oncology, 2011
201 Background: Androgen-deprivation therapy (ADT) with a luteinising hormone-releasing hormone a... more 201 Background: Androgen-deprivation therapy (ADT) with a luteinising hormone-releasing hormone analogue (LHRHa) is widely used in the management of prostate cancer. LHRHa suppresses testosterone to castrate levels but can lead to long term toxicities including osteoporosis, adverse metabolic effects and cardiovascular (CV) complications. Transcutaneous oestrogen is an attractive potential alternative to ADT. This approach circumvents first-pass hepatic metabolism and so should avoid the CV effects previously reported with oral oestrogen in men with prostate cancer. Castrate levels of testosterone, and hence prostate cancer outcomes, are expected to be equivalent but the side-effects associated with ADT will potentially be avoided. Methods: PATCH is a multi-centre phase II randomized study of 254 men with locally advanced or metastatic prostate cancer assigned (2:1) to either oestrogen patches (Merck FemSeven 100mcg/24hr; 4 patches changed twice-weekly, reducing to 3 after 4 weeks) ...
European Journal of Cancer, 2015
is an emerging area of research, emphasising the need for accurate and feasible physical capacity... more is an emerging area of research, emphasising the need for accurate and feasible physical capacity measurements in this group. The purpose of this study was to evaluate the validity of the predicted VO 2peak from the Ekblom-Bak test (EBT) and theÅstrand predicition model (ÅT). Material and Methods: Six patients with breast cancer stage I-IIIa undergoing chemotherapy treatment (mean ± standard deviation body mass, height, and age; 70.68±10.25kg; 1.64±0.09m; and 51±11 yrs respectively) participated in the study. Oxygen uptake was determined with a metabolic chart (OxygenPro, Jaeger GmbH, Germany) validated against the Douglas bag method (typical error=2%). EBT was performed prior to a 20 Watt incremental exercise test to peak effort on a cycle ergometer (Monark 839E, Vansbro, Sweden) for VO 2peak assessment.ÅT was used to estimate VO 2max when pedalling at 60 rpm. The mean difference and standard deviation of the differences between the EBT andÅT and measured VO 2peak respectively was calculated with Bland-Altman analysis. Results: The mean measured VO 2peak was 1.78±0.16 L•min −1. The predicted VO 2peak resulting from EBT lead to an overestimation of VO 2peak with 0.89 L•min −1 and a coefficient of variation of 23% while the predicted VO 2peak resulting from theÅT led to an overestimation of 0.41 L•min −1 with a coefficient of variation of 8% compared to the incremental exercise test to VO 2peak. Conclusions: The predicted VO 2peak from the Ekblom-Bak test, resulted in a relatively large overestimation of the cardiovascular fitness of the patients, suggesting that the use of this VO 2peak prediction model based on difference in heart rate between a low and high work load seems to be inappropriate in breast cancer patients undergoing chemotherapy treatment. This may be due to chemotherapy itself or medication received in combination with chemotherapy affecting the heart rate. However, from these findings, theÅstrand model resulted in a fairly good prediction of VO 2peak. This may in part be due to the fact thatÅstrand prediction model is based on heart rate from one work load only. Exploration of a new correction factor may be key to improve the accuracy of submaximal testing in this population. No conflict of interest. 1906 POSTER Management of BRCA 1/2 mutation carriers: 14 years of a multidisciplinary program
European Urology, 2016
Background: Luteinising hormone-releasing hormone agonists ([ 2 1 _ T D $ D I F F ] LHRHa), used ... more Background: Luteinising hormone-releasing hormone agonists ([ 2 1 _ T D $ D I F F ] LHRHa), used as androgen deprivation therapy (ADT) in prostate cancer (PCa) management, reduce serum oestradiol as well as testosterone, causing bone mineral density (BMD) loss. Transdermal oestradiol is a potential alternative to LHRHa. Objective: To compare BMD change in men receiving either LHRHa or oestradiol patches
Radiotherapy and Oncology, 2015
S690 3rd ESTRO Forum 2015 planned hospitalization. Full course of radiotherapy can be safely used... more S690 3rd ESTRO Forum 2015 planned hospitalization. Full course of radiotherapy can be safely used in older patients but they have a low tolerance to chemotherapy and frequently require dose-reduction; the effect of this chemotherapy is uncertain. EP-1277 Effect of age on rectal toxicity following radical radiotherapy to prostate cancer
Uploads
Papers by abdulla Alhasso